THC Transdermal Patch Microreservoirs for Stable 7-Day Drug Flux
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal delivery systems for cannabinoids face challenges due to their rapid metabolism and hydrophobic nature, leading to unstable concentration levels and difficulty in achieving a stable and continuous drug flux through the skin.
Innovation Solution
A transdermal therapeutic system (TTS) comprising an active agent impermeable backing layer, an adhesive layer with at least 70% polysiloxane polymer, tetrahydrocannabinol, and a solubilizer, optionally with a removable protective layer, to create a microreservoir system for sustained release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If cannabinoids are administered via conventional routes, then the active agent is rapidly metabolized in the body, but the concentration level of the active agent in the bloodstream decreases rapidly
Solution Approach 1:
The system segments the cannabinoid delivery into multiple microreservoirs distributed throughout the adhesive layer, each containing liquid cannabinoid. This segmentation allows for sustained release over multiple days, extending duration of action from hours to days while maintaining stable bloodstream concentration levels.
Solution Approach 2:
The cannabinoid is pre-loaded into liquid microreservoirs within the adhesive layer before application. This preliminary preparation ensures that the active agent is already positioned for controlled release, enabling extended duration of action and stable concentration levels without requiring frequent reapplication.
2Speed
If cannabinoids are made highly lipophilic to improve transdermal penetration, then transdermal application becomes difficult due to strong tendency to bind to tissue and protein
Solution Approach 1:
The adhesive layer acts as an intermediary between the cannabinoid microreservoirs and the skin. It contains the lipophilic cannabinoid in liquid form within microreservoirs, allowing controlled release that overcomes the binding issue while maintaining adequate penetration speed through the skin.
Solution Approach 2:
The system changes the physical state parameter of the cannabinoid by maintaining it in liquid form within microreservoirs rather than crystalline form. This parameter change enables the lipophilic cannabinoid to be released in a controlled manner, improving ease of transdermal application while maintaining penetration effectiveness.
3Device complexity
If a monolithic TTS design is used for cannabinoid delivery, then the structure is simple, but stable and continuous drug flux over prolonged periods cannot be achieved
Solution Approach 1:
The system divides the cannabinoid reservoir into multiple small liquid microreservoirs distributed throughout the adhesive layer. This segmentation provides stable and continuous drug flux over prolonged periods (up to 7 days) while maintaining relatively simple overall structure, resolving the contradiction between simplicity and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TTS formulation provides a stable and continuous drug flux of tetrahydrocannabinol through the skin for up to 7 days, maintaining consistent bloodstream concentrations.
Implementation Method 1
an adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer
Implementation Method 2
The system ensures a stable and continuous release of tetrahydrocannabinol through the skin for up to 7 days, maintaining steady concentration levels in the bloodstream
Implementation Method 3
a TTS formulation according to claim 1, in particular a transdermal therapeutic system comprising i) an active agent impermeable backing layer, ii) at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer
Data Source
AI summary
Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.